trial · primary record
Lucerastat
Fabry Disease
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 107 |
| Primary completion | 2026-10-06 |
| Primary endpoint | Treatment-emergent adverse events (AEs) |
| Registry ID | NCT03737214 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:09.575Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03737214
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.